cambridge's bluebird bio licenses delivery tech to novartis, gsk
.
.now the country may face a fine of millions of euros after its dereliction was referred to the european court of justice (ecj), the guardian reports.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
$17
OFF DEAL
GET DEAL
218 Used Today
50%
OFF DEAL
GET DEAL
181 Used Today
$20
OFF DEAL
GET DEAL
200 Used Today
now the country may face a fine of millions of euros after its dereliction was referred to the european court of justice (ecj), the guardian reports. .
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance. .
OFF DEAL
218 Used Today
OFF DEAL
181 Used Today
OFF DEAL
200 Used Today